Who
Dipti Amin
Director
Company insider
Files Form 4 as: Director, Lineage Cell Therapeutics.
In numbers
- Trades disclosed
- 9
- Buys
- 1
- Sells
- 0
- Bought
- $57K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 20 Apr 2021
- Last trade
- 1 Jul 2026
- Last filed
- 2 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Jul 2026filed 2 Jul 2026 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 1 Jul 2025filed 2 Jul 2025 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 1 Jul 2024filed 3 Jul 2024 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 1 Jul 2023filed 3 Jul 2023 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 1 Jul 2022filed 6 Jul 2022 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 28 Mar 2022filed 29 Mar 2022 | LCTX Lineage Cell TherapeuticsBiotechnology | SEC FORM 4 Bought | $57K35,000 at $1.63 | filing |
| 1 Jul 2021filed 1 Jul 2021 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 20 Apr 2021filed 22 Apr 2021 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
News
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Shares Down 1.2% – What's Next?LCTX · dailypolitical.com · 17 Oct 2026
0 headlines in the last 90 days name Dipti Amin; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.